Submitted an FDA IDE application in May 2026 for a U.S. CBGM clinical study; closed an Australia long-term feasibility study following a reassessment.
Quarterly loss narrows as expenses decline
GlucoTrack posted a GAAP net loss of USD 3.81 million for the quarter ended June 30, 2026, narrowing from USD 4.76 million.
R&D expense fell to USD 2.02 million from USD 3.15 million, due to lower accrued product and manufacturing costs for the CBGM model.
G&A costs declined to USD 1.38 million from USD 1.65 million, on lower professional fees and personnel costs.
Cash and cash equivalents dropped to USD 1.12 million at June 30, 2026 from USD 7.38 million at Dec. 31, 2025; accumulated deficit totaled USD 159.99 million.
GCTK•
